Trial Profile

A Randomized, Double-Blind, Phase 2 Pilot Study of VLX-1005 Versus Placebo in Participants With Suspected Heparin Induced Thrombocytopenia Treated With Background Standard of Care

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 04 Mar 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs VLX-1005 (Primary)
Indications Heparin-induced thrombocytopenia and thrombosis syndrome
Focus Proof of concept; Therapeutic Use
Acronyms ALATHEA
Sponsors Veralox Therapeutics

Most Recent Events

24 Feb 2026 According to a Veralox Therapeutics media release,End-of-Phase 2 Meeting Scheduled for March 2026.
24 Feb 2026 Primary endpoint (Time to recovery of platelet count to 150 X 10^9/L in patients with a positive serotonin release assay)has not been met,According to a Veralox Therapeutics media release.
24 Feb 2026 Results presented at Cadrenal Therapeutics media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com